The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.
Legislative & Regulatory Positions
Stay up-to-date on recent legislative and regulatory developments and actions that AMCP has taken on behalf of members that impact managed care pharmacy professionals. AMCP's position statements are regularly reviewed and updated by the AMCP Board of Directors.
AMCP believes that a health care delivery system that is based upon a competitive marketplace will provide greater value to patients and payers than a system that is one‐size‐fits‐all that relies on centralized governmental controls and regulatory mandates.
AMCP opposes statutory and regulatory proposals that unduly restrict the ability of pharmacists working within managed care organizations from utilizing tools and services that are essential for the management of a prescription drug benefitFind out about Regulation of the Prescription Drug Benefit.
AMCP stands against racial and health care injustice. AMCP is committed to 1) mitigating disparities related to optimal medication use, 2) advancing conversations by calling for pertinent submissions to the Journal of Managed Care + Specialty Pharmacy (JMCP) and conducting partnership forum(s), 3) incorporating health equity goals into the strategic plan, and 4) supporting impactful education and policy.
AMCP supports the use of preferred pharmacy networks as a way of providing additional options to incentivize higher quality care and improve cost-effectiveness.
AMCP supports the use of MAC pricing as a managed care tool to encourage the dispensing of cost saving generic drugs and thereby benefiting the overall health care system.
AMCP believes that to provide the greatest value to Americans who need prescription drugs, market forces must effectively ensure that manufacturers of similar drugs compete with one another to establish reasonable pricing levels and maintain consumer access to needed therapies. While government has a responsibility to protect consumers against anti-competitive activity, the government must not establish rules that have the unintended effect of undermining competition.
AMCP supports off‐label use of FDA‐approved drugs when medically appropriate and necessary, but opposes government‐mandated coverage of specific pharmaceuticals, whether for FDA‐approved or off‐label uses.
AMCP supports the implementation and expanded use of health information technology (HIT), including electronic health records and electronic prescribing.
AMCP supports regulatory and legislative provisions relating to opioid management that ensure appropriate patient access and treatment of uncontrolled pain, while limiting abuse and diversion of opioids and opioid potentiators. .
AMCP believes that payors must have the flexibility to use mail service delivery of prescription drugs as a component of their prescription drug benefit.
AMCP supports the use of value frameworks as a resource for determining the value of pharmaceuticals and other health technologies when the Frameworks are based on sound methods using good scientific evidence and economic models.
